IBDEI16U ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20202,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20202,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Bladder
 ;;^UTILITY(U,$J,358.3,20202,1,4,0)
 ;;=4^Z85.51
 ;;^UTILITY(U,$J,358.3,20202,2)
 ;;=^5063428
 ;;^UTILITY(U,$J,358.3,20203,0)
 ;;=Z85.528^^84^930^89
 ;;^UTILITY(U,$J,358.3,20203,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20203,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Kidney
 ;;^UTILITY(U,$J,358.3,20203,1,4,0)
 ;;=4^Z85.528
 ;;^UTILITY(U,$J,358.3,20203,2)
 ;;=^5063430
 ;;^UTILITY(U,$J,358.3,20204,0)
 ;;=Z85.6^^84^930^80
 ;;^UTILITY(U,$J,358.3,20204,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20204,1,3,0)
 ;;=3^Personal Hx of Leukemia
 ;;^UTILITY(U,$J,358.3,20204,1,4,0)
 ;;=4^Z85.6
 ;;^UTILITY(U,$J,358.3,20204,2)
 ;;=^5063434
 ;;^UTILITY(U,$J,358.3,20205,0)
 ;;=Z85.72^^84^930^104
 ;;^UTILITY(U,$J,358.3,20205,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20205,1,3,0)
 ;;=3^Personal Hx of Non-Hodgkin Lymphomas
 ;;^UTILITY(U,$J,358.3,20205,1,4,0)
 ;;=4^Z85.72
 ;;^UTILITY(U,$J,358.3,20205,2)
 ;;=^5063436
 ;;^UTILITY(U,$J,358.3,20206,0)
 ;;=Z85.79^^84^930^94
 ;;^UTILITY(U,$J,358.3,20206,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20206,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Lymphoid,Hematpoetc & Rel Tissue
 ;;^UTILITY(U,$J,358.3,20206,1,4,0)
 ;;=4^Z85.79
 ;;^UTILITY(U,$J,358.3,20206,2)
 ;;=^5063437
 ;;^UTILITY(U,$J,358.3,20207,0)
 ;;=Z85.820^^84^930^83
 ;;^UTILITY(U,$J,358.3,20207,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20207,1,3,0)
 ;;=3^Personal Hx of Malig Melanoma of Skin
 ;;^UTILITY(U,$J,358.3,20207,1,4,0)
 ;;=4^Z85.820
 ;;^UTILITY(U,$J,358.3,20207,2)
 ;;=^5063441
 ;;^UTILITY(U,$J,358.3,20208,0)
 ;;=Z85.828^^84^930^98
 ;;^UTILITY(U,$J,358.3,20208,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20208,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Skin
 ;;^UTILITY(U,$J,358.3,20208,1,4,0)
 ;;=4^Z85.828
 ;;^UTILITY(U,$J,358.3,20208,2)
 ;;=^5063443
 ;;^UTILITY(U,$J,358.3,20209,0)
 ;;=Z85.71^^84^930^78
 ;;^UTILITY(U,$J,358.3,20209,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20209,1,3,0)
 ;;=3^Personal Hx of Hodgkin Lymphoma
 ;;^UTILITY(U,$J,358.3,20209,1,4,0)
 ;;=4^Z85.71
 ;;^UTILITY(U,$J,358.3,20209,2)
 ;;=^5063435
 ;;^UTILITY(U,$J,358.3,20210,0)
 ;;=Z65.8^^84^930^138
 ;;^UTILITY(U,$J,358.3,20210,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20210,1,3,0)
 ;;=3^Psychosocial Circumstance Related Problems
 ;;^UTILITY(U,$J,358.3,20210,1,4,0)
 ;;=4^Z65.8
 ;;^UTILITY(U,$J,358.3,20210,2)
 ;;=^5063185
 ;;^UTILITY(U,$J,358.3,20211,0)
 ;;=Z86.11^^84^930^115
 ;;^UTILITY(U,$J,358.3,20211,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20211,1,3,0)
 ;;=3^Personal Hx of Tuberculosis
 ;;^UTILITY(U,$J,358.3,20211,1,4,0)
 ;;=4^Z86.11
 ;;^UTILITY(U,$J,358.3,20211,2)
 ;;=^5063461
 ;;^UTILITY(U,$J,358.3,20212,0)
 ;;=Z86.13^^84^930^82
 ;;^UTILITY(U,$J,358.3,20212,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20212,1,3,0)
 ;;=3^Personal Hx of Malaria
 ;;^UTILITY(U,$J,358.3,20212,1,4,0)
 ;;=4^Z86.13
 ;;^UTILITY(U,$J,358.3,20212,2)
 ;;=^5063463
 ;;^UTILITY(U,$J,358.3,20213,0)
 ;;=Z86.73^^84^930^112
 ;;^UTILITY(U,$J,358.3,20213,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20213,1,3,0)
 ;;=3^Personal Hx of TIA & Cereb Infrc w/o Residual Deficits
 ;;^UTILITY(U,$J,358.3,20213,1,4,0)
 ;;=4^Z86.73
 ;;^UTILITY(U,$J,358.3,20213,2)
 ;;=^5063477
 ;;^UTILITY(U,$J,358.3,20214,0)
 ;;=Z86.79^^84^930^75
 ;;^UTILITY(U,$J,358.3,20214,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20214,1,3,0)
 ;;=3^Personal Hx of Circulatory System Diseases
 ;;^UTILITY(U,$J,358.3,20214,1,4,0)
 ;;=4^Z86.79
 ;;^UTILITY(U,$J,358.3,20214,2)
 ;;=^5063479
